marimastat has been researched along with batimastat in 24 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (batimastat) | Trials (batimastat) | Recent Studies (post-2010) (batimastat) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 347 | 6 | 56 |
| Protein | Taxonomy | marimastat (IC50) | batimastat (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | 0.025 | |
| Interstitial collagenase | Homo sapiens (human) | 0.3158 | |
| Low affinity immunoglobulin epsilon Fc receptor | Homo sapiens (human) | 0.1 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.3029 | |
| Stromelysin-1 | Homo sapiens (human) | 1.1205 | |
| Matrilysin | Homo sapiens (human) | 3.5012 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.0066 | |
| Neutrophil collagenase | Homo sapiens (human) | 0.7 | |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 1.2 | |
| Collagenase 3 | Homo sapiens (human) | 0.005 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 0.025 | |
| Matrix metalloproteinase-14 | Homo sapiens (human) | 0.5715 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.0149 | |
| Snake venom metalloproteinase BaP1 | Bothrops asper (terciopelo) | 1.2 | |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | 0.025 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (45.83) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hori, N; Ikeda, S; Inoue, S; Ohishi, Y; Okada, Y; Tsujishita, H; Yamamoto, M | 1 |
| Albert, DH; Bouska, JJ; Davidsen, SK; Elmore, I; Florjancic, AS; Giesler, JR; Goodfellow, CL; Guo, Y; Magoc, TJ; Marcotte, PA; Morgan, DW; Sheppard, GS; Summers, JB; Xu, L | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Kuwano, M; Ono, M | 2 |
| Dickson, RB; Hawkins, MJ; Wojtowicz-Praga, SM | 1 |
| McCann, PP; Rasmussen, HS | 1 |
| Denis, LJ; Verweij, J | 1 |
| Hooper, NM; Hussain, I; Karran, EH; Parvathy, S; Turner, AJ | 2 |
| Bouterfa, H; Hanke, A; Kerkau, S; Mueller, JG; Roosen, K; Tonn, JC; Vince, GH; Wagner, S | 1 |
| Hande, KR; Nelson, AR; Rothenberg, ML | 1 |
| Nakajima, M | 1 |
| Hooper, NM; Parkin, ET; Trew, AJ; Turner, AJ | 1 |
| Eckhardt, SG; Hidalgo, M | 1 |
| Banai, S; Fishbein, I; Gertz, SD; Golomb, G; Margolin, L; Perez, LS; Reich, R | 1 |
| Augustin, HG | 1 |
| Didziapetriene, J; Kadziauskas, J; Stanciūte, D | 1 |
| Cho, SH; Duin, EC; Hong, JW; Jambovane, S; Kim, SK; Yun, JY | 1 |
| Altevogt, P; Arnold, A; Cerwenka, A; Fiegler, N; Moldenhauer, G; Paschen, A; Rose-John, S; Schlecker, E; Sucker, A; Textor, S; von Strandmann, EP | 1 |
| Arias, AS; Gutiérrez, JM; Rucavado, A | 1 |
| Bicknell, AB; Lakshminarayanan, K; Layfield, HJ; Mehmi, A; Patel, K; Ravishankar, D; Salim, A; Sonavane, M; Trim, SA; Vaiyapuri, R; Vaiyapuri, S; Vallance, TM; Williams, HF | 1 |
| Dharmasivam, M; Park, KC; Richardson, DR | 1 |
| Lin, IT; Lin, MY; Wang, IJ; Wu, YC | 1 |
11 review(s) available for marimastat and batimastat
| Article | Year |
|---|---|
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured | 1997 |
Matrix metalloproteinase inhibitors.
Topics: Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Down-Regulation; Drugs, Investigational; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydroxamic Acids; Metalloendopeptidases; Molecular Weight; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Protease Inhibitors; Protein Kinase C; Proteins; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases | 1997 |
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Enzyme Inhibitors; Female; Hemangioma; Humans; Hydroxamic Acids; Melanoma; Metalloendopeptidases; Mice; Ovarian Neoplasms; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Skin Neoplasms; Thiophenes | 1997 |
Matrix metalloproteinase inhibitors: present achievements and future prospects.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neoplasms; Phenylalanine; Protease Inhibitors; Thiophenes | 1997 |
[Neovascularization and tumor development].
Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatins; Humans; Hydroxamic Acids; Interferons; Interleukin-12; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Phenylalanine; Plasminogen; Sesquiterpenes; Thalidomide; Thiophenes | 1998 |
[Matrix metalloproteinase inhibitors].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Metastasis; Organic Chemicals; Phenylalanine; Thiophenes | 2000 |
The role of proteolysis in Alzheimer's disease.
Topics: ADAM Proteins; ADAM17 Protein; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Biotinylation; Endopeptidases; Humans; Hydroxamic Acids; Membrane Lipids; Membrane Proteins; Metalloendopeptidases; Nerve Tissue Proteins; Phenylalanine; Presenilin-1; Presenilin-2; Protease Inhibitors; Rats; Thiophenes | 2000 |
Development of matrix metalloproteinase inhibitors in cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes | 2001 |
[Angiogenesis research--quo vadis?].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Cell Communication; Drug Evaluation, Preclinical; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Ephrins; Forecasting; Growth Substances; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Lymphokines; Metalloendopeptidases; Mice; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phenylalanine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research; Signal Transduction; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Expression of matrix metalloproteinases in patients with malignant tumors].
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Clinical Trials as Topic; Diphosphonates; Disease Progression; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Prognosis; Protease Inhibitors; Thiophenes; Time Factors; Tissue Inhibitor of Metalloproteinases | 2004 |
The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Disease Progression; Drug Design; Drug Screening Assays, Antitumor; Extracellular Fluid; Extracellular Vesicles; Humans; Hydroxamic Acids; Iron; Iron Chelating Agents; Kallikreins; Matrix Metalloproteinases; Molecular Targeted Therapy; Neoplasm Proteins; Oxaprozin; Peptide Hydrolases; Phenylalanine; Protease Inhibitors; Protein Kinases; Pyridines; Thiophenes; Thiosemicarbazones; Zinc | 2020 |
13 other study(ies) available for marimastat and batimastat
| Article | Year |
|---|---|
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Topics: Amino Acid Sequence; Dipeptides; Humans; Hydroxamic Acids; Ligands; Matrix Metalloproteinases, Membrane-Associated; Metalloendopeptidases; Models, Molecular; Mutation; Phenylalanine; Protease Inhibitors; Protein Conformation; Structure-Activity Relationship; Thiophenes | 1998 |
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
Topics: Gelatinases; Hydroxamic Acids; Ketones; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Protease Inhibitors; Structure-Activity Relationship | 1998 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Alzheimer's amyloid precursor protein alpha-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Drug Screening Assays, Antitumor; Endopeptidases; Enzyme Inhibitors; Humans; Hydroxamic Acids; Metalloendopeptidases; Microvilli; Neuroblastoma; Peptidyl-Dipeptidase A; Phenylalanine; Swine; Tetrazolium Salts; Thiophenes; Tumor Cells, Cultured; Zinc | 1998 |
The amyloid precursor protein (APP) and the angiotensin converting enzyme (ACE) secretase are inhibited by hydroxamic acid-based inhibitors.
Topics: Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cell Line; Cells, Cultured; Endopeptidases; Endothelium, Vascular; Humans; Hydroxamic Acids; Peptidyl-Dipeptidase A; Phenylalanine; Protease Inhibitors; Protein Processing, Post-Translational; Thiophenes; Umbilical Veins | 1998 |
Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.
Topics: Animals; Brain; Cell Aggregation; Cell Division; Collagenases; Enzyme Inhibitors; Fetus; Gelatinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 7; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Neurons; Phenylalanine; Rats; Rats, Inbred Strains; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1999 |
New drugs on the horizon: matrix metalloproteinase inhibitors.
Topics: Antineoplastic Agents; Azepines; Biphenyl Compounds; Humans; Hydroxamic Acids; Metalloendopeptidases; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Thiophenes | 1999 |
Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade.
Topics: Angioplasty, Balloon; Animals; Arteries; Cell Movement; Constriction, Pathologic; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Hydroxamic Acids; Hyperplasia; Male; Matrix Metalloproteinase Inhibitors; Muscle, Smooth, Vascular; Oligopeptides; Phenylalanine; Rats; Receptors, Vitronectin; Thiophenes; Tunica Intima | 2002 |
Log-scale dose response of inhibitors on a chip.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Kinetics; Lab-On-A-Chip Devices; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Microchip Analytical Procedures; Neoplasms; Phenylalanine; Sensitivity and Specificity; Spectrometry, Fluorescence; Thiophenes | 2011 |
Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; B7 Antigens; Cell Line, Tumor; Dipeptides; HCT116 Cells; HeLa Cells; Humans; Hydroxamic Acids; Killer Cells, Natural; Lymphocyte Activation; MCF-7 Cells; Melanoma; Membrane Proteins; Natural Cytotoxicity Triggering Receptor 3; Phenylalanine; Protease Inhibitors; RNA Interference; RNA, Messenger; RNA, Small Interfering; Thiophenes; Tumor Escape; Up-Regulation | 2014 |
Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom.
Topics: Animals; Cameroon; Dose-Response Relationship, Drug; Ghana; Hemorrhage; Hydroxamic Acids; Lung; Metalloproteases; Mice; Peptidomimetics; Phenylalanine; Snake Bites; Thiophenes; Viper Venoms; Viperidae | 2017 |
Repurposing Cancer Drugs Batimastat and Marimastat to Inhibit the Activity of a Group I Metalloprotease from the Venom of the Western Diamondback Rattlesnake,
Topics: Animals; Antineoplastic Agents; Antivenins; Binding Sites; Blood Platelets; Catalytic Domain; Collagen; Crotalid Venoms; Crotalus; Drug Repositioning; Erythrocytes; Fibrin; Fibrinolysis; Hemolysis; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Molecular Docking Simulation; Phenylalanine; Protein Binding; Protein Conformation; Structure-Activity Relationship; Substrate Specificity; Thiophenes | 2020 |
Stepwise candidate drug screening for myopia control by using zebrafish, mouse, and Golden Syrian Hamster myopia models.
Topics: Animals; Atropine; Cricetinae; Disease Models, Animal; Drug Evaluation, Preclinical; Embryo, Nonmammalian; Hydroxamic Acids; Lumican; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Morpholinos; Myopia; Phenylalanine; Sclera; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Zebrafish; Zebrafish Proteins | 2021 |